Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.83 |
| ▸ | ARG2 | P78540 | 4/20 | 0.52 |
| ▸ | ARG1 | P05089 | 3/20 | 0.52 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | NOS1 | P29475 | 3/20 | 0.46 |
| ▸ | NOS3 | P29474 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.45 |
| ▸ | GRM6 | O15303 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL8562830 | 1.00 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL28331087 | 0.96 | GSR (0.77) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL445453 | 0.92 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Ornithine Aketoglutarate SCHEMBL27686822 | 0.92 | GSR (0.69) | GSRARG2ARG1NOS2CYP1A2 | |
| Lysine SCHEMBL17102268 | 0.92 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL22534312 | 0.92 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL7343 | 0.91 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL1645 | 0.91 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL456381 | 0.91 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL20362357 | 0.91 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105277712-B | A kind of method for identifying the modification of lysine ε amino side chains monomethylation | 杭州景杰生物科技有限公司 | 2017-07-11 | — | — | CN | claimed |
| US-20050112709-A1 | Histone h3methyltransferase polypeptide | CHROMA THERAPEUTICS LIMITED (GB) | 2005-05-26 | — | — | US | claimed |
| EP-1458858-A2 | HISTONE H3 METHYLTRANSFERASE POLYPEPTIDE | Chroma Therapeutics Limited (GB) | 2004-09-22 | — | — | EP | claimed |
| WO-2003048352-A2 | HISTONE H3 METHYLTRANSFERASE POLYPEPTIDE | CHROMA THERAPEUTICS LTD (GB) | 2003-06-12 | — | — | WO | claimed |
| CN-118616094-A | Artificial enzyme with laccase-like catalytic activity, and preparation method and application thereof | 天津大学 | 2024-09-10 | — | — | CN | disclosed |
| EP-4387972-A1 | CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCER | Biomea Fusion, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-12018032-B2 | Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction | BIOMEA FUSION, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-4384179-A1 | COVALENT INHIBITORS OF MENIN-MLL INTERACTION FOR DIABETES MELLITUS | Biomea Fusion, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-115607552-B | Combination use of substituted 4-aminoisoindoline-1, 3-dione compounds and a second active agent | 新基公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118076357-A | Covalent inhibitors of Mennin-MLL interactions for diabetes | 拜欧米富士恩公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240158750-A1 | STROMA-FREE NK CELL DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4013756-B1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-05-08 | — | — | EP | disclosed |
| WO-2002090578-A9 | METHODS AND MEANS OF HISTONE METHYLATION | UNIV CAMBRIDGE TECH (GB) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003004050-A1 | METHYLATION OF HISTONE H4 AT ARGININE 3 | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-01-16 | — | — | WO | disclosed |
| WO-2002090578-A2 | METHODS AND MEANS OF HISTONE METHYLATION | CHROMA THERAPEUTICS LIMITED (GB) | 2002-11-14 | — | — | WO | disclosed |
| US-20020081638-A1 | Method for identifying compounds altering higher-order chromatin-dependent chromosome stability | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2002-06-27 | — | — | US | disclosed |
| WO-2001094620-A1 | SCREENING-METHOD FOR MODULATORS OF METHYLTRANSFERASE-DEPENDENT CHROMOSOME STABILITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2001-12-13 | — | — | WO | disclosed |
| EP-1162274-A1 | Method for identifying compounds modifying methyltransferase-dependent chromosome stability | Boehringer Ingelheim International GmbH (DE) | 2001-12-12 | — | — | EP | disclosed |
| EP-0844890-A1 | THE USE OF BILE ACID DERIVATIVES | THE UNIVERSITY OF BIRMINGHAM (GB) | 1998-06-03 | — | — | EP | disclosed |
| WO-1997006829-A1 | THE USE OF BILE ACID DERIVATIVES | THE UNIVERSITY OF BIRMINGHAM (GB) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018032-B2 | Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction | MLLT1, MEN1, MALT1 | GSR 4628/4885ARG2 2259/4885ARG1 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.